Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
can you compute gV total sales inception to date and put a treble $ damage on that number. Might be extremely impressive, we may own Hikma!
I'll second Capt. Beers number, he has the charts.
I like the way you think.
marjac WINS!
marjac must be prescient!
NO SCRIPTS?
Jasbg let me say that since you first appeared on this site your English has improved dramatically, now maybe better than mine. Now the challenge is to master words that sound the same but are spelled differently which is a challenge to many brought up in the language. Marry Christmas.
Wouldn’t it be a hoot if following our Feb. oral arguments the court ruled on our rule 60 petition and rendered its opinion in our favor on March 30.
Ditto Jimcal22, and kudos to our crack legal team. I for one think our chances of success are greater than even.
Merry Christmas everyone and may 2022 more Han make up for the trials of the past two years. God bless you all.
While I do not agree with marjac’s decision to fight this next battle from the foxhole, his decision must be honored since he and the team have brought us this far. I just feel that we have made so much headway that it’s a shame to enter this phase with what I sense is not our strongest effort. That being said I believe our chances of success are quite good (I.e. not a Hail Mary). I don’t believe that our shareholder suit against a third party is so unique that it needs to be adjudicated and decided. But lawyers on board would have a better feel for this. I believe the court wants to get to the issue of “skinny labels” and the abuse thereof. I also believe that the February forum will see several questions by the jurists more pertinent to rule 60 than rule 24, which will be a giant “tell” as to the direction and scope of the decision. There is no reason they can’t overturn Du and remand the case with explicit instructions on establishing the validity of patents. While unlikely, we will have a much stronger feel for our chances based on these proceedings.
“Whether they work or not”, the people or the drugs?
Marjac, is it possible that Hickman is fighting so hard on rule 24 and not addressing rule 60 in their briefs is because they know their rule 60 position is unwinnable? In other words win rule 24 or capitulate! My fear is we win rule 24 and Hickman high tails it to Amarin to settle and Amarin asks us to drop the suit as part of a settlement, to which I say stick it where TLDS.
Though when we win this case, they will grant themselves a large bonus in shares to further dilute us.
I contributed the first two rounds, might as well make it 3, in for a penny, in for a dollar. I have the utmost confidence in marjac and am indebted to him and his “committee” for putting together what I am confident will be a winning case. They will study this case in law schools in the future.
marjac, you the man! Congratulations and thank you. Is the hearin on rule 24 or 60? I hope the latter.
Is this new?
@Amarincorp @pfizer DYK that the Chinese Society of Cardiology recommends the use of VASCEPA (ethyl eicosapentaenoate) for TG Management & Prevention of ASCVD? https://t.co/ZGTgwUcw2Q pic.twitter.com/r5tpoFGe9a
— Mike Everts (@GeoWizz_) December 14, 2021
Interesting Dr. Mercola article on CVD risk measurements
https://media.mercola.com/ImageServer/Public/2021/December/PDF/cholesterol-levels-in-people-who-had-heart-attacks-pdf.pdf
FFS $ AMRN, is there an infilled gap in this stock below current levels? How low do we have to go to fill it?
Thank you for the response. I have long valued your contributions to the board and look forward to our day of vindication.
Is it true, as posted on ST, that rafun has sold his AMRN shares and is no longer a shareholder? Disappointing if true, but understandable. Will he at least post script numbers for us for awhile? Would be nice. I will miss his contributions to this site.
Some pretty incredible COVID numbers, the kind we had hoped for from MITIGATE.
Park https://www.theepochtimes.com/mkt_breakingnews/melatonin-affects-thrombosis-sepsis-and-covid-mortality-rate_4105459.html?utm_source=newsnoe&utm_medium=email&utm_campaign=breaking-2021-12-06-4&mktids=92053afd0e525ad2cb0c2b4b29a3a0d1&est=0m96NAseJkXFXgh7xHf%2Bpg2lyXS%2BB9DAu3y6yAVfE4qaWNIMymsmSV%2FN9NODvGRR
Wow, at 4g a day amazons price for Vascepa is over $600 per 90 days and generics is just under $1000. Tough numbers to swallow.
where is Hindu Kush? I miss his always enlightening posts.
Without increasing death rates. In PFE’s safety trials for its vaccine, death rate was 50% higher than placebo at almost 1 per 1000 vaccinated.
And COVID (CCP) isn’t? No gain of function here.
I had a flu shot in fall of 2013, 2 weeks later I was paralyzed from the waist down with GBS. While I can walk today I suffer a number of issues all from the shot messing up my immune system. Told never to get another vaccine. I don’t envy anyone who voluntarily or involuntarily takes any of these experimental jabs. God protect you.
Rahm Emanuels brother, Dr Ezekiel Emanuel was part of the “think” tank that conjured up Obama care and is a proponent of geriatricide, though in other less obvious terms when he was working on that piece of garbage. He cloaked it in other language but it amounted to denying health care to people over a certain age or with certain conditions. He is now with the NIH. The government is not concerned one bit that the jab kills. In fact they may look at that as a societal benefit.
An excellent and concise letter. Thank you for the effort.
If anyone knows the email address of Michael Kalb, SVP, CFO, would you please share it with me?
In the fourth quarter of 2019 I thought I would sell my AMRN in the 1st quarter of 20, deferring capital gains taxes into the next year and perhaps see some added appreciation because sales were growing at a 50% annual rate and Europe and China approvals were on the horizon. Then COVID and Du, two unanticipated diseases, knocked the stock for a loop. Should I have sold in Dec. ‘19? In retrospect yes, but was it stupid to think you could wait a month or two to sell? Not with what I knew and expected at the time. But the last two years have been the most painful of my 80 years and have necessitated many changes in my life style. Unfortunately we can’t go back and change things only look forward. The company is worth much more than $4, but what the upside today is, I can only guess. $15-20-25. Probably the low end of that range without a significant improvement somewhere.
I’m surprised by the early morning reaction to the PI2 results since obviously there was nothing in the price for the study, one way or the other. Of more importance to my thinking is the larger MITIGATE study at Kaiser with results due in 1Q 22. Though expectation for this study likely need to be lowered, positive results could result in Kaiser and other large medical groups adopting Vascepa as an adjunct for COVID treatment. In terms of future catalysts, we may get a clue to October vaskepa sales tomorrow, and there is the China approval likely by year end.
I hate to say it but our fate may rely on the outcome of our two suits, marjac and infringement. With a win by Marjac a sure home run if we prevail. It would eliminate gv and result in huge treble damages and perhaps even punitive damages due to the generics cheating ways.
Until then this stock looks to be mired in $4-6 range. While many of the long term holders may have reduced there cost basis enough to show a negligible profit, the opportunity costs lost are staggering. Thanks JT and BOD.
What is the probability Edingham will get final approval to market Vascepa in China before year end (50 days and counting down)?
Monday we'll see if AMRN is a 3 handle stock or a % handle stock. Myself, I'm pulling for Marc Brady.
I’m sure there are, on this board, medical professionals and others that consider Dr Mercola a quack. However if they will lay their skepticism aside, they will find the following article both interesting and informative if not valuable as we all look to guard ourselves against the threat of COVID.
https://articles.mercola.com/sites/articles/archive/2021/11/08/cleveland-clinic-melatonin.aspx?ui=ff340c8dbd45cc819d4a24e4c8404772abc3ca8f52ef1a47742a0bc8bfe56f7a&sd=20150731&cid_source=dnl&cid_medium=email&cid_content=art3ReadMore&cid=20211108&mid=DM1037775&rid=1316376933
After this weeks reaction to a middling earnings release and conference call, I am preparing myself, both spiritually and emotionally for P2 results that are less than the hyped expectations, and the price washout that will follow. It won’t be until marjac wins the rule 60 proceedings that I expect any real large positive price improvement unless China come through soon and Germany smashes expectations.